On October 11, 2016, EpimAb and Kymab, a leading human monoclonal antibody biopharmaceutical company, announced a cross-licensing and development agreement to develop bispecific therapeutic antibodies against multiple targets. The parties will focus their efforts on immuno-oncology and will combine EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform to generate multiple bispecific antibodies combined with antibodies sourced from Kymab’s proprietary Kymouse® platform. Kymab will have the development and commercialization rights to these bispecifics in all geographical regions outside of China, and, under the terms of the cross license agreement, EpimAb will have the rights for the China market.
On June 6, 2016 EpimAb and Innovent Biologics, one of the leading biopharmaceutical companies in China, announced a multiple target agreement for the development of bispecific antibodies. Under the terms of the agreement, Innovent gained access to EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform to develop multiple bispecific antibodies for the Chinese market, including the right to out-license the developed programs outside of China.
On April 23, 2018, EpimAb Biotherapeutics and Zhejiang Teruisi Biopharmaceutical announced a development collaboration on a bispecific antibody program discovered by EpimAb. Under the terms of the agreement, Zhejiang Teruisi Biopharmaceutical, Inc. gained access to EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig®) program FIT012/TRS008 to develop it for the Chinese market. EpimAb retains all commercial rights to the program outside of China. In return for commercialization rights in China, EpimAb is eligible to receive an upfront payment and total success-based milestones of up to US-$21 MM, plus royalties.